K. Priest

Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Claudia Allemani, Tomohiro Matsuda, V Di Carlo et al. · The Lancet · 2018 · 6.2K citations · Full text

Medicine, Biostatistics, Oncology +17

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Paul J. Ross, S. Ashley, A. Norton et al. · British Journal of Cancer · 2004 · 477 citations · Full text

Medicine, Oncology, Chemotherapy +13

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

PA Ellis, IE Smith, MC Nicolson et al. · British Journal of Cancer · 1995 · 176 citations · Full text

Medicine, Oncology, Pharmacology +15

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial

E O’Brien, David Watkins, C. Ryan et al. · Annals of Oncology · 2005 · 123 citations · Full text

Medicine, Oncology, Chemotherapy +6

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

Helmout Modjtahedi, Tamas Hickish, Margery Nicolson et al. · British Journal of Cancer · 1996 · 102 citations · Full text

Medicine, Oncology, Molecular Oncology +12